医学
嵌合抗原受体
多发性骨髓瘤
肿瘤科
内科学
耐火材料(行星科学)
不利影响
硼替佐米
免疫疗法
癌症
天体生物学
物理
作者
Thomas Martin,Deepu Madduri,Lida Pacaud,Saad Z. Usmani
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-07-27
卷期号:19 (34): 2297-2311
被引量:17
标识
DOI:10.2217/fon-2022-1317
摘要
Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Approval in the EU followed for patients with ≥3 prior therapies. At median 28-month follow-up, the pivotal CARTITUDE-1 trial showed a 98% response rate (83% stringent complete response); median progression-free survival had not been reached, and adverse events could be managed with supportive therapy. Cilta-cel efficacy and safety in earlier lines of therapy, and its optimal sequencing in a complex treatment landscape are important areas of investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI